FCB-Pharmicell to cerebrate GMP facility in Germany

Published: 2006-11-24 06:56:00

Updated: 2006-11-24 06:56:00

FCB-Pharmicell, a local biopharmaceutical company, said it will complete the construction of its GMP facility in Germany on November 27, this year, to develop a new drug for the treatment of stroke using stem cells.

The company said its preclinical studies for stroke is to be completed in Febr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK